Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis

por Bacci, Elizabeth D., DeLozier, Amy M., Lin, Chen-Yen, Gaich, Carol L., Rooney, Terence, Hoffman, Richard, Wyrwich, Kathleen W.
Publicado 2017

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial

por Michaud, Kaleb, Pope, Janet E., Emery, Paul, Zhu, Baojin, Gaich, Carol L., DeLozier, Amy M., Zhang, Xiang, Dickson, Christina L., Smolen, Josef S.
Publicado 2019

Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation

por Bingham, Clifton O., Gaich, Carol L., DeLozier, Amy M., Engstrom, Kathryn D., Naegeli, April N., de Bono, Stephanie, Banerjee, Pixy, Taylor, Peter C.
Publicado 2019

Correction to: Use of daily electronic patient-reported outcome (PRO) diaries in randomized controlled trials for rheumatoid arthritis: rationale and implementation

por Bingham, Clifton O., Gaich, Carol L., DeLozier, Amy M., Engstrom, Kathryn D., Naegeli, April N., de Bono, Stephanie, Banerjee, Pixy, Taylor, Peter C.
Publicado 2019

Psychometric properties of the single-item measure, severity of worst tiredness, in patients with moderately to severely active rheumatoid arthritis

por Bacci, Elizabeth D., DeLozier, Amy M., Lin, Chen-Yen, Gaich, Carol L., Zhang, Xiang, Rooney, Terence, de Bono, Stephanie, Hoffman, Richard, Wyrwich, Kathleen W.
Publicado 2017

Estimating the response and economic burden of rheumatoid arthritis patients treated with biologic disease-modifying antirheumatic drugs in Taiwan using the National Health Insuran...

por Shi, Qiang, Li, Ko-Jen, Treuer, Tamas, Wang, Bruce C. M., Gaich, Carol L., Lee, Chien-Hsun, Wu, Wen-Shuo, Furnback, Wesley, Tang, Chao-Hsiun
Publicado 2018

Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAM

por Fautrel, Bruno, Kirkham, Bruce, Pope, Janet E., Takeuchi, Tsutomu, Gaich, Carol, Quebe, Amanda, Zhu, Baojin, de la Torre, Inmaculada, De Leonardis, Francesco, Taylor, Peter C.
Publicado 2019

Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA

por Radawski, Christine, Genovese, Mark C., Hauber, Brett, Nowell, W. Benjamin, Hollis, Kelly, Gaich, Carol L., DeLozier, Amy M., Gavigan, Kelly, Reynolds, Maria, Cardoso, Anabela, Curtis, Jeffrey R.
Publicado 2019

Patient-reported outcomes from a phase III study of baricitinib in patients with conventional synthetic DMARD-refractory rheumatoid arthritis

por Emery, Paul, Blanco, Ricardo, Maldonado Cocco, Jose, Chen, Ying-Chou, Gaich, Carol L, DeLozier, Amy M, de Bono, Stephanie, Liu, Jiajun, Rooney, Terence, Chang, Cecile Hsiao-Chun, Dougados, Maxime
Publicado 2017

Clinical outcomes in patients switched from adalimumab to baricitinib due to non-response and/or study design: phase III data in patients with rheumatoid arthritis

por Tanaka, Yoshiya, Fautrel, Bruno, Keystone, Edward C, Ortmann, Robert A, Xie, Li, Zhu, Baojin, Issa, Maher, Patel, Himanshu, Gaich, Carol L, de Bono, Stephanie, Rooney, Terence P, Taylor, Peter C
Publicado 2019

Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON)

por Smolen, Josef S, Kremer, Joel M, Gaich, Carol L, DeLozier, Amy M, Schlichting, Douglas E, Xie, Li, Stoykov, Ivaylo, Rooney, Terence, Bird, Paul, Sánchez Bursón, Juan Miguel, Genovese, Mark C, Combe, Bernard
Publicado 2017

Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study

por Dougados, Maxime, van der Heijde, Désirée, Chen, Ying-Chou, Greenwald, Maria, Drescher, Edit, Liu, Jiajun, Beattie, Scott, Witt, Sarah, de la Torre, Inmaculada, Gaich, Carol, Rooney, Terence, Schlichting, Douglas, de Bono, Stephanie, Emery, Paul
Publicado 2017

Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study

por Keystone, Edward C, Taylor, Peter C, Tanaka, Yoshiya, Gaich, Carol, DeLozier, Amy M, Dudek, Anna, Zamora, Jorge Velasco, Cobos, Jose Arturo Covarrubias, Rooney, Terence, de Bono, Stephanie, Arora, Vipin, Linetzky, Bruno, Weinblatt, Michael E
Publicado 2017

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial

por Taylor, Peter C., Lee, Yvonne C., Fleischmann, Roy, Takeuchi, Tsutomu, Perkins, Elizabeth L., Fautrel, Bruno, Zhu, Baojin, Quebe, Amanda K., Gaich, Carol L., Zhang, Xiang, Dickson, Christina L., Schlichting, Douglas E., Patel, Himanshu, Durand, Frederick, Emery, Paul
Publicado 2019

Patient-reported outcomes of baricitinib in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment

por Schiff, Michael, Takeuchi, Tsutomu, Fleischmann, Roy, Gaich, Carol L., DeLozier, Amy M., Schlichting, Douglas, Kuo, Wen-Ling, Won, Ji-Eon, Carmack, Tara, Rooney, Terence, Durez, Patrick, Shaikh, Saeed, Hidalgo, Rodolfo Pardo, van Vollenhoven, Ronald, Zerbini, Cristiano A. F.
Publicado 2017